title: Bevacizumab for malignant gliomas.
abstract: Malignant gliomas are the most common and aggressive primary brain tumors in adults. Despite optimal treatment with surgery, radiotherapy, and temozolomide, tumor recurrences are frequent and patients with malignant gliomas continue to have poor prognoses. Malignant gliomas are often highly vascularized, and significant advances have been made in the last few decades in our understanding of the mechanisms of tumor angiogenesis. Recently, bevacizumab, an antibody against vascular endothelial growth factor, has demonstrated significant activity in recurrent glioblastomas, resulting in US Food and Drug Administration approval and raising the prospect for other antiangiogenic drugs now entering clinical trials.
authors.affiliation: Neuro-Oncology Branch, National Cancer Institute, National Institute for Neurological Disorders and Stroke, National Institutes of Health, 9030 Old Georgetown Rd, Bloch Bldg 82, Room 225, Bethesda, MD 20892, USA.
authors.forename: Fabio M
authors.initials: FM
authors.lastname: Iwamoto
authors.forename: Howard A
authors.initials: HA
authors.lastname: Fine
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D001932:Brain Neoplasms / Q000378:metabolism / Q000628:therapy*; D005910:Glioma / Q000378:metabolism / Q000628:therapy*; D006801:Humans; D009389:Neovascularization, Pathologic / Q000628:therapy; D042442:Vascular Endothelial Growth Factors / Q000378:metabolism
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042442:Vascular Endothelial Growth Factors; D000068258:Bevacizumab